Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BRCA wild-type
i
Other names:
BRCA1, BRCC1, PPP1R53, RNF53, Breast cancer 1, early onset, BRCA2, BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, Breast cancer 2, early onset
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
672
;
675
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
BRCA wild-type
Ovarian Cancer
BRCA wild-type
Ovarian Cancer
bevacizumab + olaparib + atezolizumab
Sensitive: C3 – Early Trials
AACR 2023 - 5 days (New C3)
bevacizumab + olaparib + atezolizumab
Sensitive
:
C3
AACR 2023 - 5d
bevacizumab + olaparib + atezolizumab
Sensitive: C3 – Early Trials
AACR 2023 - 5 days
bevacizumab + olaparib + atezolizumab
Sensitive
:
C3
AACR 2023 - 5 days - (New C3)
BRCA wild-type
Ovarian Cancer
BRCA wild-type
Ovarian Cancer
rucaparib
Sensitive: A2 - Guideline
rucaparib
Sensitive
:
A2
rucaparib
Sensitive: A2 - Guideline
rucaparib
Sensitive
:
A2
BRCA wild-type
Ovarian Cancer
BRCA wild-type
Ovarian Cancer
ABT-888
Sensitive: B - Late Trials
ABT-888
Sensitive
:
B
ABT-888
Sensitive: B - Late Trials
ABT-888
Sensitive
:
B
BRCA wild-type
Triple Negative Breast Cancer
BRCA wild-type
Triple Negative Breast Cancer
olaparib + alpelisib
Sensitive: C3 – Early Trials
olaparib + alpelisib
Sensitive
:
C3
olaparib + alpelisib
Sensitive: C3 – Early Trials
olaparib + alpelisib
Sensitive
:
C3
BRCA wild-type
Breast Cancer
BRCA wild-type
Breast Cancer
talazoparib
Sensitive: C3 – Early Trials
talazoparib
Sensitive
:
C3
talazoparib
Sensitive: C3 – Early Trials
talazoparib
Sensitive
:
C3
BRCA wild-type
Triple Negative Breast Cancer
BRCA wild-type
Triple Negative Breast Cancer
ACR-368
Sensitive: C3 – Early Trials
ACR-368
Sensitive
:
C3
ACR-368
Sensitive: C3 – Early Trials
ACR-368
Sensitive
:
C3
BRCA wild-type
Ovarian Cancer
BRCA wild-type
Ovarian Cancer
pembrolizumab + bevacizumab + olaparib
Sensitive: C3 – Early Trials
pembrolizumab + bevacizumab + olaparib
Sensitive
:
C3
pembrolizumab + bevacizumab + olaparib
Sensitive: C3 – Early Trials
pembrolizumab + bevacizumab + olaparib
Sensitive
:
C3
BRCA wild-type
Triple Negative Breast Cancer
BRCA wild-type
Triple Negative Breast Cancer
talazoparib + ZEN-3694
Sensitive: C3 – Early Trials
talazoparib + ZEN-3694
Sensitive
:
C3
talazoparib + ZEN-3694
Sensitive: C3 – Early Trials
talazoparib + ZEN-3694
Sensitive
:
C3
BRCA wild-type
Ovarian Cancer
BRCA wild-type
Ovarian Cancer
bortezomib
Sensitive: C3 – Early Trials
bortezomib
Sensitive
:
C3
bortezomib
Sensitive: C3 – Early Trials
bortezomib
Sensitive
:
C3
BRCA wild-type
Ovarian Cancer
BRCA wild-type
Ovarian Cancer
carboplatin + paclitaxel
Sensitive: C3 – Early Trials
carboplatin + paclitaxel
Sensitive
:
C3
carboplatin + paclitaxel
Sensitive: C3 – Early Trials
carboplatin + paclitaxel
Sensitive
:
C3
BRCA wild-type
Triple Negative Breast Cancer
BRCA wild-type
Triple Negative Breast Cancer
MLN4924
Sensitive: D – Preclinical
MLN4924
Sensitive
:
D
MLN4924
Sensitive: D – Preclinical
MLN4924
Sensitive
:
D
BRCA wild-type
Ovarian Cancer
BRCA wild-type
Ovarian Cancer
olaparib + ART12
Sensitive: D – Preclinical
olaparib + ART12
Sensitive
:
D
olaparib + ART12
Sensitive: D – Preclinical
olaparib + ART12
Sensitive
:
D
BRCA wild-type
Ovarian Cancer
BRCA wild-type
Ovarian Cancer
olaparib + cediranib + 3-AP
Sensitive: D – Preclinical
olaparib + cediranib + 3-AP
Sensitive
:
D
olaparib + cediranib + 3-AP
Sensitive: D – Preclinical
olaparib + cediranib + 3-AP
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login